Is 100 million stem cells a lot? Counts, viability and dose
It depends on what was counted. The real dose is viable, identified MSCs per kilogram, and it can vary by 10× to 10,000× between two clinics quoting the same headline number.
See "100M cells" multiplied outMedically reviewed by the physician team at Hospital Angeles · October 2026
What does "100 million stem cells" leave out?
"100 million stem cells." It's the most quoted number in this space, and the one with the least information content. What gets counted, what's alive, what's MSC, what reaches the joint or the bloodstream: these are different numbers, and the headline figure usually conflates all of them.
Two clinics both quote "100 million cells." One ships frozen vials made in a cGMP lab, with each batch released against a viability spec of ≥95% post-thaw and an identity panel confirming the product is mesenchymal stem cells (MSCs). The other counts every nucleated cell that comes out of a centrifuge, most of which are not stem cells at all, and quotes the total.
The headline matches. The delivered MSC dose does not. The ratio can be 10× or 10,000×.
This page unpacks the four numbers that matter and what to ask any clinic before you compare quotes.
Stem cell count: what is being counted, and what isn't?
The first number on a vial label is a cell count. It sounds simple, but a count means nothing without specifying which cells are being counted and how. Three counts coexist in this field, and they are not interchangeable: TNC (every cell with a nucleus), MSC count (cells confirmed as MSCs by flow cytometry against the ISCT criteria: CD73⁺ CD90⁺ CD105⁺ and CD45⁻ CD34⁻ CD14⁻ CD19⁻ HLA-DR⁻), and viable MSC count (MSCs that are also alive).
Same headline. Different contents.
Both vials say "100M cells" on the label. One is mostly debris-adjacent cells. The other is 95% confirmed MSCs by flow cytometry. Each dot below represents ~1% of the vial.
Same-day BMAC / SVF 100M total nucleated cells
- RBC precursors, lymphocytes, fibroblasts, debris-adjacent
- ~99.99%
- Confirmed MSCs (CD73⁺ CD90⁺ CD105⁺)
- ~0.01%
- Actual MSCs in vial
- ~10,000
cGMP allogeneic MSC product 100M lab-expanded cells
- Other / non-MSC fraction
- ≤5%
- Confirmed MSCs (CD73⁺ CD90⁺ CD105⁺, CD45⁻ CD34⁻ CD14⁻ CD19⁻ HLA-DR⁻)
- ≥95%
- Actual MSCs in vial
- ~95,000,000
This is why the very first question is not "how many cells?" It's "how many MSCs?" and "how is identity confirmed?"
Read moreShow less
A "100 million cell" same-day bone-marrow concentrate might contain 100 million nucleated cells, of which perhaps 1,000 to 10,000 are MSCs. A "100 million cell" lab-expanded cGMP MSC product contains 100 million cells that are ≥95% identified as MSCs by flow. Same headline. ~10,000× difference in delivered MSCs.
Stem cell viability: how many are alive?
A cell count counts cells. A viability assay tells you how many of them are alive. Dead cells are still cells. They still scatter light, still get counted by an automated hemocytometer, still show up in the headline number. They do nothing biologically.
At Celva, viability is held to ≥95% post-thaw at infusion, measured after thaw, right before treatment. That's the number that matters: not the viability at freeze (which marketing pages quote), but the viability of the cells actually entering the patient.
Read moreShow less
Post-thaw is the harder number to hold, because thawing is where viability slips, so a high post-thaw figure reflects the care taken at harvest, controlled-rate freezing, and storage, not just a healthy starting culture. A well-run cGMP product has both at-freeze and post-thaw viability on the Certificate of Analysis. If only one is quoted, ask for the other. More on the cGMP release panel.
Four ways to measure alive.
Read moreShow less
| Assay | Method | Precision | Use |
|---|---|---|---|
| Trypan blue | Dye excluded by intact membranes · manual count under microscope | ±5–10% | Quick check |
| 7-AAD | Fluorescent stain via flow cytometry · excludes from live cells | ±1–2% | Release |
| Annexin V / 7-AAD | Detects both apoptotic and dead cells · gold standard for research | ±1–2% | Research |
| Acridine / PI | Dual fluorescent stain · automated counters (NucleoCounter, etc.) | ±2–3% | Release |
Effective dose: count × identity × viability
Put the three numbers together and you get an effective dose: the number of viable, identified MSCs actually delivered. The math is multiplicative, and small drops at each step compound quickly.
"100M cells" multiplied out.
Identical headline numbers. Below, the math each one represents. The result column is what reaches the patient.
Same headline. Different universe of delivered dose.
What do the cells deliver?
An effective-dose number tells you how many viable, identified cells reached the patient. It does not tell you how much therapeutic signal those cells will produce once they're in. That second question is the secretome: the complex mix of cytokines, growth factors, and extracellular vesicles (exosomes) that cells release into the environment around them. The secretome is the delivery mechanism for all six primary mechanisms: anti-inflammatory, anti-fibrotic, immunomodulatory, pro-angiogenic, neurotrophic, anti-apoptotic. It is what the cells do, once they are alive and where they are supposed to be.
Read moreShow less
Two preparations with the same count, the same identity panel, and the same viability can still produce very different secretomes. Cell age (a newborn cord cell vs. a sixty-year-old marrow cell), passage number (low vs. high), the manufacturing media, the cryopreservation method, the thaw protocol: all of it influences what the cells secrete once they are dosed. The reason cGMP manufacturing matters is not that the count on the box is more accurate. It is that everything upstream of that count is consistent enough to produce a consistent secretome.
For most patients, the practical takeaway is short: a count without viability is misleading; a viable count without a characterized secretome is half the picture; and a "potency" line item on a certificate of analysis is the only thing that ties the upstream manufacturing to a number that maps to clinical response.
Weight-adjusted dosing: cells per kilogram
Clinical research on MSC therapies doses by weight, not by flat-rate vials. Cells delivered systemically distribute through a body proportional to its size. A 60 kg patient and a 100 kg patient given the "same vial" receive meaningfully different per-kilogram doses.
The convention in MSC clinical research is cells per kilogram (cells/kg). Typical research doses sit in the 1 to 2 million cells/kg range for IV infusion, with some protocols going higher. A 70 kg patient at 1M/kg = 70M MSCs total. At 2M/kg = 140M total.
The 100 kg patient gets the same vial.
Three dosing conventions, applied to the same two patients.
Not scaled. 1.7M/kg for the small patient. 1.0M/kg for the large patient. Two different doses, marketed as the same.
Tied to billing tiers, not weight. "Upsell tiers" that don't reflect actual dosing logic. Beware of vial counts framed as therapeutic intensity.
Scales with the patient. Same per-kg, different total cells. The convention used in published clinical research.
Ask any clinic quoting a flat number: "Is this dose adjusted for my weight? If not, what's the per-kilogram?" A serious operation answers immediately, often with a chart. An operation that quotes a flat dose for every patient regardless of size is not following clinical-research dosing convention.
Read moreShow less
Local injections into a specific joint or disc are dosed differently, by volume and site geometry, not body weight, because the cells stay in that compartment. Systemic IV infusions are the ones that should scale with weight.
What does an honest dose statement look like?
An honest clinic, given the question "how much am I getting?", can answer it in five numbers. A clinic that can't is selling a headline.
What you should be able to get on paper.
- Total cell count per vial
The headline. Useful only with the next four numbers, never alone.
Per vial - MSC identity
% of cells positive for CD73, CD90, CD105 by flow cytometry, and negative for CD45, CD34, CD14, CD19 and HLA-DR. ISCT minimal criteria.
By flow - Post-thaw viability
The spec the clinic releases against, plus the actual measured value for your batch.
At infusion - Source tissue and lab
Where the cells came from, who manufactured them, what passage they were used at.
On CoA - Dose per kilogram
For systemic infusion. Or per-site volume for local injection. Not a flat-rate vial count.
cells/kg
These five numbers should appear on the patient-facing summary, the Certificate of Analysis for the batch, or both. A clinic that cannot produce them on request is either disorganized or hiding the answer. Neither is acceptable for a treatment of this magnitude.
The headline is not the dose.
"Millions of stem cells" is a marketing unit, not a clinical one. The real dose is viable, identified MSCs per kilogram and it can vary by 10× to 10,000× between two clinics quoting the same headline number.
Three numbers determine the real dose: count, identity (% MSCs by flow), and post-thaw viability. Multiply them. Divide by your weight. That's what you compare across quotes.
Ask for % MSC by flow
Not "stem cells." A flow-cytometry-confirmed MSC percentage against ISCT criteria. The single largest source of headline-versus-dose gap.
Ask for post-thaw viability
The release spec the clinic batches against, and the measured value for your batch. Not the at-freeze number from marketing.
Ask for cells per kilogram
For systemic infusion. A flat dose for every patient regardless of body weight is not how MSC clinical research is done.